MicroTherapeutics
This article was originally published in The Gray Sheet
Executive Summary
Liquid embolic system developer secures $56 mil. staged financing from institutional investor Warburg Pincus, the Irvine, California-based company announces May 29. Proceeds will go towards ongoing clinical trials and marketing efforts for the Onyx liquid embolic material, which is delivered through MTI's proprietary microcatheters for the treatment of neurovascular disease, including brain aneurysms and arteriovenous malformations. The equity placement will occur in two stages. The first round, expected to close by the end of the week of May 28, involves the placement of about 2 mil. shares at $3.75 per share, for a total of almost $7.5 mil. before transaction costs. The second stage will involve the offering of approximately 8.1 mil. shares at $6 per share, generating net proceeds of $48.5 mil. If other investors with which MTI already has agreements choose to participate in this financing, proceeds from the second round could increase to as much as $59 mil
You may also be interested in...
Micro Therapeutics
Developer of Onyx liquid embolic material raises $48.7 mil. via sale of 8.1 mil. shares at $6 each to Micro Investment LLC, managed by institutional investor Warburg Pincus Equity Partners, LP. In conjunction with the earlier sale in June of 2 mil. shares at $3.75 each, the most recent financing brings aggregate proceeds to about $56 mil. and gives Micro Investment a greater than 50% stake in the company (1"The Gray Sheet" June 4, 2001, p. 26). Proceeds will support Irvine, California-based Micro Therapeutics' ongoing Onyx clinical trials and marketing programs, as well as debt repayment. Onyx is CE marked in Europe for the treatment of brain aneurysms, arteriovenous malformations and certain peripheral applications. Pivotal U.S. trials are underway for aneurysms and AVMs
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”